Please login to the form below

Not currently logged in
Email:
Password:

erlotinib

This page shows the latest erlotinib news and features for those working in and with pharma, biotech and healthcare.

J&J’s bispecific lung cancer antibody nabs FDA breakthrough status

J&J’s bispecific lung cancer antibody nabs FDA breakthrough status

This type of mutation occurs in tumours that aren’t sensitive to treatment with first- and second-generation small-molecule EGFR inhibitors like AstraZeneca’s Iressa (gefitinib), Roche’s Tarceva (erlotinib)

Latest news

More from news
Approximately 4 fully matching, plus 71 partially matching documents found.

Latest Intelligence

  • Market access opportunities in China Market access opportunities in China

    For example, although Roche's Tarceva (erlotinib hydrochloride) has not been included in any reimbursement lists in China, it has paved the way by collaborating with the China Charity Federation to

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Novocure’s chief commercial officer to step down Novocure’s chief commercial officer to step down

    Previously, he was senior vice president for sales and marketing at OSI Pharmaceuticals, where he led the global commercialisation of Tarceva (erlotinib) from 2003 to 2011.

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).

  • Astellas poaches new oncology head from Takeda Astellas poaches new oncology head from Takeda

    She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.

  • Cipla appoints Novartis’ Subhanu Saxena as CEO Cipla appoints Novartis’ Subhanu Saxena as CEO

    Cipla has also been busy challenging big pharma patents, and in September won a four-year battle to market its own version of Roche's cancer drug  Tarceva  (erlotinib).

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics